🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

34 results for “ipilimumab” Clear

  1. anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  2. ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

    Second Affiliated Hospital of Soochow University

    Liver Cancer

    phase 2 small molecule active

    1 trial

  3. linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  4. nivolumab, ipilimumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule completed

    1 trial

  5. A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT

    Fondazione Telethon ETS

    High-Risk, Surgically Resectable Melanoma

    phase 1 other active

    1 trial

  6. Ipilimumab

    VACCINEX, INC.

    Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

    phase 1 mab active

    1 trial

  7. Ipilimumab

    Regeneron UK Limited

    Stage III Prostate Cancer

    phase 1 mab terminated

    1 trial

  8. LENVATINIB, NIVOLUMAB, CABOZANTINIB, LENVATINIB, NIVOLUMAB, AXITINIB, CABOZANTINIB, PEMBROLIZUMAB, IPILIMUMAB, AXITINIB, AXITINIB

    Fondazione Telethon ETS

    metastatic or locally advanced renal cell carcinoma

    approved small molecule active

    1 trial

  9. PEMBROLIZUMAB , NIVOLUMAB , IPILIMUMAB

    Disc Medicine

    Melanoma

    approved small molecule active

    1 trial

  10. Ipilimumab

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources